Journal of Cystic Fibrosis
Publisher: Elsevier · ISSN 1569-1993 · 73 articles
- Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis
- Density fluctuations of Burkholderia and Achromobacter in cystic fibrosis sputum
- A disrupted microbial network and an ecological shift towards anaerobes in NTM-infected cystic fibrosis patients
- The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France
- Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population
- Dupilumab in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) in cystic fibrosis patients
- Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis
- Altered responsiveness to photic stimuli contribute to circadian disruption in cystic fibrosis
- Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis
- Expiratory lung MRI: a simple, sensitive method to quantify and visualise regional gas trapping in cystic fibrosis
- Lung mucus burden and treatment response assessed by MRI in the post-modulator era
- Intestinal organoids as a platform for functional evaluation of ASO-mediated splicing modulation in cystic fibrosis
- Apical hyperosmotic challenge upregulates aquaporin-3 in human airway epithelia
- Investigation of HE4 expression concerning epithelial-mesenchymal transition (EMT) in cystic fibrosis epithelial cells
- Clinical, functional and therapeutic evaluation of CFTR variant I507del
- CFTR knock-out mice exhibit impaired renal compensation to dietary NaCl depletion
- Contents
- News article
- Non-invasive colorectal cancer screening in cystic fibrosis: Promise, pitfalls, and future directions
- Overnutrition in cystic fibrosis- did we get it wrong?
- Is the gut a reservoir of non-tuberculous mycobacteria in people with cystic fibrosis?
- Persistence of large P. aeruginosa aggregates despite reduced airway burden in people with cystic fibrosis on CFTR modulator therapy
- Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study
- A functional comparison of vanzacaftor/tezacaftor/deutivacaftor and elexacaftor/tezacaftor/ivacaftor in patient-derived intestinal organoids with rare CFTR variants
- Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: An open-label proof-of-concept study
- Lack of clinical change in longitudinal vibration controlled transient elastography among children with cystic fibrosis and poor association with non-invasive biomarkers of liver disease
- Hepatic steatosis in adults on CFTR modulators is commonly associated with cardiometabolic criteria consistent with metabolic dysfunction-associated steatotic liver disease
- Normalization of total bilirubin after switch from elexacaftor/tezacaftor/ivacaftor to vanzacaftor/tezacaftor/deutivacaftor in patients with cystic fibrosis and Gilbert’s syndrome
- Impact of ETI therapy on bone health, body composition and cardiopulmonary fitness in children with CF
- Obesity in adults with cystic fibrosis following prescription of elexacaftor/tezacaftor/ivacaftor